Featured Research

from universities, journals, and other organizations

New treatment method safe, effective for advanced melanoma patients, study suggests

Date:
June 7, 2010
Source:
University of Pittsburgh Schools of the Health Sciences
Summary:
Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly to the liver's blood vessels, according to a new study.

Patients undergoing treatment for melanoma that has spread to the liver may respond well to chemotherapy delivered directly into the liver's blood vessels, according to a study sponsored by the National Cancer Institute and Delcath Systems Inc., and led by James F. Pingpank, M.D., associate professor of surgery, University of Pittsburgh School of Medicine, and surgical oncologist with UPMC Cancer Centers.

The results were presented in an oral presentation on June 5 in Chicago at the 46th annual meeting of the American Society of Clinical Oncology (ASCO).

"Once melanoma spreads to the liver, a patient's life expectancy typically ranges from six to nine months," said Dr. Pingpank. "We hoped this study would not only show an increase in progression-free survival rates for these patients, but also lead to a standard of care for the disease."

The phase III trial enrolled 93 patients from 10 different sites across the country between February 2006 and October 2009. Its primary goal was to double the length of hepatic progression-free survival for patients with melanoma that had spread to the liver. Patients received either percutaneous hepatic perfusion (PHP) with the drug melphalan, meaning the chemotherapy was delivered directly into the blood vessels of the liver, or the treatment considered the best alternative regimen by their treating physician. If a patient not receiving PHP had disease progression, he or she could cross over to the PHP arm of the trial.

"Not only did we achieve our goal, we surpassed it," said Dr. Pingpank. "This is particularly exciting because so far oncologists haven't been able to recommend a standard of care for patients with melanoma that has spread to the liver. PHP appears to control tumors in the liver and extend life expectancy for these patients, whether their melanoma began as skin cancer or as ocular melanoma, a less common form of the disease that starts in the eye. Fifty percent of ocular melanoma patients will experience liver metastasis, so these findings are crucial for them."

Melanoma is a rare form of cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide. Ocular melanoma will be diagnosed in approximately 2,500 adults this year.

Other sites involved in the study include the Surgery Branch of the NCI, Bethesda, Md.; John Wayne Cancer Institute, Santa Monica, Calif.; H.Lee Moffitt Cancer Center, Tampa, Fla.; University School of Maryland Medicine, Baltimore; The University of Texas M.D. Anderson Cancer Center, Houston; Atlantic Melanoma Center, Morristown, N.J.; Rad Imaging Associates, Englewood, Colo.; Albany Medical Center Hospital, Albany, N.Y.; and St. Luke's Hospital and Health Network in Bethlehem, Pa.


Story Source:

The above story is based on materials provided by University of Pittsburgh Schools of the Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Schools of the Health Sciences. "New treatment method safe, effective for advanced melanoma patients, study suggests." ScienceDaily. ScienceDaily, 7 June 2010. <www.sciencedaily.com/releases/2010/06/100606104823.htm>.
University of Pittsburgh Schools of the Health Sciences. (2010, June 7). New treatment method safe, effective for advanced melanoma patients, study suggests. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2010/06/100606104823.htm
University of Pittsburgh Schools of the Health Sciences. "New treatment method safe, effective for advanced melanoma patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/06/100606104823.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins